Please assess the completion status of the following clinical trial:

Trial Title: The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* 18-72 years of age~* Subjects scheduled to undergo a rotator cuff repair with a subacromial decompression by one of the protocol investigators~Exclusion Criteria:~* Planned concomitant glenoid labral repair~* Previous open shoulder surgery~* Neurological deficit or other disability involving the surgical extremity~* Anyone with a documented allergy to bupivicaine~* Subjects that are not mentally competent to give consent~* Pregnant women~* Subjects with an intolerance to hydrocodone or oxycodone and/or brand name equivalent combination medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- EXPAREL 1.3 % in 20 ML Injection (Type: OTHER): EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% \[13.3 mg/mL\]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~* size of surgical site~* volume required to cover the area~* individual patient factors that may impact the safety of an amide local anesthetic~* maximum doe of 266 mg (20 mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).